On the bull side, the shares look cheap, and the dividend yield is high. GSK has slumped from above 1,700p in June last year to 1,320p today. That leaves the …
For 2018, EPS guidance was given, as last year, bearing in mind the uncertainty over the timing and impact of possible generic competition to GSK's Advair asthma drug in the US. In the event of no substitutable generic competitor, …
Dr Vivienne Cox, Non Executive Director, bought 416 shares in the company on the 7th February 2018 at a price of 1278.00p. The Director now holds 1,897 shares representing 0.00% of the shares in issue.
SEE ALSO: The massive $500 billion budget deal could be coming at exactly the wrong time for the economy » READ …
I initiated a position in GSK recently. The stock is attractively priced, partly due to currency effects, and the weak pound will continue to be a tailwind for the business. The company returned to growth, but it needs to gain more momentum. …
Portfolio Grader currently ranks GlaxoSmithKline Plc (NYSE:GSK) a Sell. The methodology for investing incorporated in this analytical tool developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week from a fundamental …
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn't want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing …
NASDAQ5mon
Glaxo's rise in May was precipitated by two catalysts. First, the drugmaker's new managerial team, headed by CEO Emma Walmsley (who took over in March), has been indicating that they might be open to accelerating the company's …
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing …